5-[2-(3,4-Dihydro-1H-isoquinolin-2-yl)-ethoxy]-1,4-dihydro-quinoxaline-2,3-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 5-[2-(3,4-Dihydro-1H-isoquinolin-2-yl)-ethoxy]-1,4-dihydro-quinoxaline-2,3-dione
• 英文别名: 5-[2-(3,4-dihydro-1H-isoquinolin-2-yl)ethoxy]-1,4-dihydroquinoxaline-2,3-dione
• 化学式: C₁₉H₁₉N₃O₃
• 分子量: 337.378
• InChiKey: RELMMIIMOZVOMD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  70.7
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-ethoxy]-6-nitro-phenylamine 生成 5-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-ethoxy]-1,4-dihydro-quinoxaline-2,3-dione.quarter hydrate 、 5-[2-(3,4-Dihydro-1H-isoquinolin-2-yl)-ethoxy]-1,4-dihydro-quinoxaline-2,3-dione
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• 5-AMINOALKOXY-1,4-DIHYDROQUINOXALINE-2,3-DIONES BEING DOPAMINE AGONISTS
  申请人：AMERICAN HOME PRODUCTS CORPORATION

  公开号：EP0963372A1

  公开（公告）日：1999-12-15
• Combination of a dopamine D2-receptor agonist and tiotropium or a derivative therof for treating obstructive airways and other inflammatory diseases
  申请人：Yeadon Michael

  公开号：US20070117788A1

  公开（公告）日：2007-05-24

  The present invention relates to a combination of therapeutic agents useful in the treatment of obstructive airways and other inflammatory diseases comprising (I) a dopamine D2-receptor agonist that is therapeutically effective in the treatment of said diseases when administered by inhalation; together with (II) an anti-cholinergic agent consisting of a member selected from the group consisting of tiotropium and derivatives thereof that is therapeutically effective in the treatment of said diseases when administered by inhalation; as well as to a method of treating said obstructive airways and other inflammatory diseases comprising administering to said mammal by inhalation a therapeutically effective amount of said combination of therapeutic agents; and a pharmaceutical composition comprising a pharmaceutically acceptable carrier together with said combination of therapeutic agents; and a package containing a pharmaceutical composition for insertion into a device capable of simultaneous or sequential delivery of said pharmaceutical composition in the form of an aerosol or dry powder dispersion to said mammal, where said device is a metered dose inhaler or a dry powder inhaler. It is preferred that said dopamine D2-receptor agonist component be bromocriptine mesylate, naxagolide hydrochloride, cabergoline, pergolide mesylate, quinpirole hydrochloride, or ropinirole hydrochloride; and that said anti-cholinergic agent component be tiotropium bromide.
• [EN] 5-AMINOALKOXY-1,4-DIHYDROQUINOXALINE-2,3-DIONES BEING DOPAMINE AGONISTS<br/>[FR] 5-AMINOALCOXY-1,4-DIHYDROQUINOXALINE-2,3-DIONES EN TANT QU'AGONISTES DE LA DOPAMINE
  申请人：——

  公开号：WO1998035948A1

  公开（公告）日：1998-08-20

  [EN] This invention relates to compounds of Formula (I) wherein: R<1> and R<2> are independently selected from hydrogen, straight-chain and branched alkyl group having up to 10 carbon atoms or -(CH2)mAr where Ar is phenyl, naphthyl or thienyl, each optionally substituted by one or two substituents selected independently from C1-C6 alkyl, halogen, C1-C6 alkoxide and trifluoromethyl; or NR<1>R<2> is 1,2,3,4-tetrahydroquinolin-1-yl or 1,2,3,4-tetrahydroisoquinolin-2-yl; m is 1-5; n is 1 or 2; Y is halogen, C1-C6 alkyl, and C1-C6 alkoxy; or the pharmaceutically acceptalbe salts thereof, which are dopamine D2 agonists and therefore useful in the treatment of psychoses and Parkinson's disease.
  [FR] Cette invention concerne des composés de la formule (I) dans laquelle R<1> et R<2> sont sélectionnés indépendamment entre l'hydrogène, un groupe alkyle à chaîne droite et ramifiée présentant jusqu'à dix atomes de carbone ou -(CH2)mAr où Ar représente phényle, naphtyle ou thiényle, chacun facultativement substitué par un ou deux substituants sélectionnés indépendamment entre alkyle C1-C6, halogène, alcoxyde C1-C6 et trifluorométhyle; ou NR<1>R<2> représente 1,2,3,4-tétrahydroquinoline-1-yl ou 1,2,3,4-tétrahydroisoquinoline-2-yl; m est compris entre 1 et 5; n représente 1 ou 2; Y représente halogène, alkyle C1-C6 et alcoxy C1-C6; ou leurs sels pharmaceutiquement acceptables, lesquels constituent des agonistes de la dopamine D2 et sont par conséquentes utiles dans le traitement de psychoses et de la maladie de Parkinson's.